Alector

Alector Employees

11 people indexed:

Arnon Rosenthal

Co-Founder, Chief Executive Officer, and Director

0bg5u.6g1d12xkd@kj74k2g.fg7 Sign up to see email

viiiq.dqg7iqp51@4pv6x08.i8v Sign up to see email
Clare Hunt

Chief People Officer

54k3y.3vy4@01j364s.s8z Sign up to see email

f3pz0.wsjb@7q0wv6v.vbq Sign up to see email
Danielle Pasqualone

General Counsel

0v9j9vhb.j854700x2z@1xx73yy.8w3 Sign up to see email

w26vz3bx.68543b94hf@zxbwg4b.47f Sign up to see email
Gary Romano

Chief Medical Officer

kiv4.53vwp6@3w1hqb9.4ib Sign up to see email

zqix.8dw2hd@fzu642i.67j Sign up to see email
Kristina Cutter

Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer

bb9w0q03.dfh2jh@yy75828.x8x Sign up to see email

1y0x5x1d.9pf5fy@6hzvqdv.xgg Sign up to see email
Marc Grasso

Chief Financial Officer

nzy1.xk487n@4zdvfd3.dn1 Sign up to see email

w227.k158yd@052b1yy.pbu Sign up to see email
Neil Berkley

Chief Business Officer

zhpq.33992p0@9gxg9x1.8js Sign up to see email

vv6x.pxhqxdq@41uj385.0q4 Sign up to see email
Norah Conway

Senior Vice President, Portfolio and Program Management

7gk35.975qjz@04b33j8.s5b Sign up to see email

ibk42.i3k642@423ssd1.16p Sign up to see email
Peter Heutink

Chief Scientific Officer

5wysj.dxs1sz0@2d92qw6.dbj Sign up to see email

3sv5z.9vsgx80@36752yx.vjg Sign up to see email
Sara Kenkare-Mitra

President and Head of Research and Development

p12y.6qfz2xgdydxjz@bbqygqx.w9u Sign up to see email

x8bw.uxwwb8p92d60d@3d98q4g.ph5 Sign up to see email
Virginia DeJesus-Rueff

Chief of Staff and Head of Strategy

8b50pbzb.5k6p57qzh9w69@993q20p.0xb Sign up to see email

kh4hh87y.b32p1pp0091qw@b3k8b6b.16y Sign up to see email

Alector Company Information

Alector operates as a biopharmaceutical entity dedicated to the innovation of therapeutic solutions for neurodegenerative disorders such as Frontotemporal Dementia, Alzheimer’s Disease, and Amyotrophic Lateral Sclerosis. The company’s approach integrates advanced understanding in immunology, neurology, and human genetics to design medicines that leverage the body’s inherent ability to heal itself. Alector’s development strategy emphasizes the rapid integration of disease- and drug-specific insights to enhance the likelihood of clinical success. Their clinical pipeline includes a global Phase 2 trial of AL101/GSK4527226 for early Alzheimer’s Disease. Additionally, the FDA has awarded Breakthrough Therapy Designation to latozinemab for Frontotemporal Dementia associated with a Progranulin Gene Mutation (FTD-GRN). Alector also maintains an expanded access policy, detailing the availability of investigational therapies outside clinical trials. The company actively participates in healthcare conferences and has recently reported its first quarter 2024 financial results along with a business update.

Report inaccurate information